With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.934342-39-9,1-(tert-Butoxycarbonyl)-3-fluoropiperidine-3-carboxylic acid,as a common compound, the synthetic route is as follows.,934342-39-9
To a stirred solution of 1-(tert-butoxycarbonyl)-3-fluoropiperidine-3-carboxylic acid (0.400 g, 1.62 mmol) in acetone (4 ml) was added K2C03 (0.670 g, 4.86 mmol) followed by the addition ofmethyl iodide (0.689 g, 4.86 mmol) at 0C under nitrogen and the resulting mixture was stirred at rt for 12h. The resulting reaction mixture was concentrated under reduced pressure and crude was diluted with water (50 ml) and extracted with EtOAc (3 x 50 ml). Combined organic extracts were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to yield 1-(tert-butyl) 3-methyl 3-fluoropiperidine-1,3-dicarboxylate (0.400 g, 1.53 mmol; Crude). LCMS: Method C, 1.933mi MS: ES+262.58.
The synthetic route of 934342-39-9 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; MISSION THERAPEUTICS LIMITED; STOCKLEY, Martin Lee; KEMP, Mark Ian; (89 pag.)WO2018/60691; (2018); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem